FDA to investigate diabetes drug saxagliptin for possible heart failure risk

by E.j. Mundell, Healthday Reporter
FDA to investigate diabetes drug saxagliptin for possible heart failure risk
Marketed as Onglyza and Kombiglyze XR, drug appears to have no effect on heart attack or stroke risk.

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users.

In a statement, the agency said that the probe was spurred by "a study published [last September] in the New England Journal of Medicine, which reported an increased rate of hospitalization for , when the heart does not pump blood well enough."

Saxagliptin, which is marketed under the brand names Onglyza and Kombiglyze XR, is a relatively new diabetes medication that works by boosting the amount of insulin the body produces after each meal, when blood sugar levels are typically high.

The NEJM study did not find that saxagliptin had any effect on a patient's risk for heart attack or stroke.

However, "our data also show an increase in hospitalization for heart failure in patients who received saxagliptin, which was not expected and deserves further study," study chairman Dr. Eugene Braunwald, of Brigham and Women's Hospital and Harvard Medical School, said in a news release issued by the hospital when the study was published.

The research involved nearly 16,500 patients with from 26 countries. It was funded by drug makers AstraZeneca and Bristol Myers Squibb, which market saxagliptin.

The FDA said the information gleaned from the NEJM trial is considered "preliminary." The drug's makers now have until early March to submit detailed trial data to agency officials, "after which we will conduct a thorough analysis and report our findings publicly."

In the meantime, the agency said that "patients should not stop taking saxagliptin and should speak with their health care professionals about any questions or concerns."

The FDA said the probe into saxagliptin "is part of a broader evaluation of all type 2 therapies and cardiovascular risk."

Issues around the safety profiles of newer diabetes drugs gained prominence after the blockbuster medication Avandia was all but pulled from the market in 2010 due to heart safety concerns.

In a journal editorial accompanying the September NEJM study, experts noted that after Avandia gained FDA approval in 1999, one highly publicized review published in 2007 "reported a 43 percent increase in [heart attacks] and a 64 percent increase in death from cardiovascular causes" tied to use of the drug.

The editorial authors said the Avandia experience led the FDA to be highly cautious in its oversight of new diabetes medications. In 2008, the agency issued a new rule mandating that "pre-approval and post-approval studies for all new anti-diabetic drugs rule out excess cardiovascular risk."

Speaking at the time of the NEJM study's release, co-author Dr. Itamar Raz, head of the Prevention of Diabetes and Diabetes Clinical Research Center at Hadassah Medical Center in Israel, stressed that saxagliptin also showed benefits for patients.

"Patients who received saxagliptin also had better control of and a reduced need for insulin therapy," he noted. Raz added that the diabetes drug also prevented the progression of microalbuminuria, a condition that occurs when a type of protein called albumin is spilling into the urine due to kidney damage.

Still, the final chapter on saxagliptin may have to wait until the FDA issues its findings on the detailed trial data.

Meanwhile, one expert said it's not easy for the millions of Americans with type 2 diabetes to know which drug is best for them.

Dr. Tara Narula, associate director of the cardiac care unit at Lenox Hill Hospital in New York City, said at the time of the study's publication that "there currently exists a tremendous amount of confusion regarding which drugs are safe to use in patients at risk for or with established cardiovascular disease."

More information: There's more on diabetes drugs at the American Diabetes Association.

Related Stories

New diabetes drug seems safe for heart, study finds

Sep 02, 2013

(HealthDay)—The new diabetes drug Onglyza has no effect, good or bad, on a patient's risk for heart attacks, a new study finds. However, the researchers from Brigham and Women's Hospital in Boston did ...

Added benefit of saxagliptin as monotherapy is not proven

Dec 05, 2013

The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin ...

Development of new diabetes drug halted by maker

Jul 10, 2013

(HealthDay)—The development of what might have become a significant diabetes drug has been halted by its maker amid concerns that the medication raises the risk for fractures, kidney problems and heart ...

Recommended for you

Targeting drugs to reduce side effects

3 hours ago

(Medical Xpress)—Consider ice cream – the base of which is frozen cream. Ingredients are then added to make different flavours. All these flavours are distinctly different but are created from the same foundation.

Drug-related morbidity in more than ten percent of adults

Apr 22, 2014

Twelve percent of adults in Sweden have diseases related to their use of medicines. But in four cases of ten it would have been possible to avoid the undesired effects. These are the conclusions of a thesis presented at the ...

User comments